22 hours Ago By ABMN Staff
Marshall Wace LLP grew its position in Applied Therapeutics, Inc. ( NASDAQ:APLT – Free Report ) by 144.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The institutional investor owned 1,307,381 shares of the company’s stock after buying an additional 773,377 shares during the quarter. Marshall Wace LLP’s holdings in Applied Therapeutics were worth $1,124,000 at the end of the most recent quarter. A number of other hedge funds have also made changes to their positions in the company.
Hennion & Walsh Asset Management Inc. increased its position in shares of Applied Therapeutics by 18.1% in the fourth quarter.
Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock valued at $268,000 after buying an additional 47,983 shares in the last quarter. Norges Bank purchased a new position in shares of Applied Therapeutics in the fourth quarter valued at $208,000.
Wellington Management Group LLP increased its position in shares of Applied Therapeutics by 17.8% in the fourth quarter. Wellington Management Group LLP now owns 237,850 shares of the company’s stock valued at $204,000 after buying an additional 35,884 shares in the last quarter.
Barclays PLC increased its position in shares of Applied Therapeutics by 186.1% in the third quarter. Barclays PLC now owns 200,012 shares of the company’s stock valued at $1,702,000 after buying an additional 130,102 shares in the last quarter.
Finally, XTX Topco Ltd increased its position in shares of Applied Therapeutics by 178.0% in the fourth quarter. XTX Topco Ltd now owns 173,568 shares of the company’s stock valued at $149,000 after buying an additional 111,128 shares in the last quarter.
Hedge funds and other institutional investors own 98.31% of the company’s stock. Applied Therapeutics Stock Up 0.
2 % APLT opened at $0.39 on Wednesday. The business’s fifty day simple moving average is $0.
45 and its 200 day simple moving average is $2.67. Applied Therapeutics, Inc.
has a 52 week low of $0.30 and a 52 week high of $10.62.
The firm has a market cap of $55.58 million, a P/E ratio of -0.24 and a beta of 1.
88. Applied Therapeutics Company Profile ( Free Report ) Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
Featured Stories Want to see what other hedge funds are holding APLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Therapeutics, Inc. ( NASDAQ:APLT – Free Report ).
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
